Management of Rituximab-Induced Skin Rash

Classification and Treatment Approach

• The American Academy of Allergy, Asthma, and Immunology recommends systemic glucocorticoids, such as methylprednisolone, for the treatment of grade 2-3 rituximab-related hypersensitivity reactions in patients with a history of skin rash, with a strength of evidence rated as high 1, 2, 3
• Skin manifestations during rituximab treatment can present as part of infusion-related reactions, serum sickness-like reactions, or other hypersensitivity reactions, affecting approximately 80% of patients, with reactions graded from 1-4, and management strategies differing based on severity 1, 3
• For grade 1-2 reactions, methylprednisolone is indicated as part of the management strategy, with a recommended dose of 40 mg IV, and slowed infusion rate, typically 50% of usual rate, along with corticosteroid premedication 1, 4
• The European Society for Medical Oncology recommends H1-antihistamines and systemic glucocorticoids for managing skin reactions, though no large validated premedication regimens exist, with a strength of evidence rated as moderate 1
• For grade 3-4 reactions, methylprednisolone (40 mg IV) or equivalent is specifically recommended 20 minutes before infusion, with allergy specialist consultation preferred before attempting rechallenge, and desensitization protocols under specialized care may be necessary, with a strength of evidence rated as high 1, 4

Dosing Recommendations and Implementation Protocol

• The American College of Clinical Pharmacology recommends methylprednisolone 40 mg IV as premedication for moderate to severe reactions, with doses ranging from 2-40 mg IV based on reaction severity, and higher pulse doses (15 mg/kg) have been used in combination protocols for severe cases 4
• For active reactions, interrupt rituximab infusion, administer methylprednisolone IV, monitor vital signs and symptoms, and resume infusion at 50% rate once symptoms resolve, with a strength of evidence rated as high 1, 4, 5
• For subsequent infusions, premedicate with methylprednisolone 40 mg IV 20-30 minutes before infusion, add diphenhydramine and acetaminophen, and consider slower initial infusion rate, with a strength of evidence rated as moderate 4, 5

Important Considerations and Caveats

• The American Academy of Allergy, Asthma, and Immunology recommends distinguishing between different types of reactions, as management differs for cytokine release syndrome versus true allergic reactions, with a strength of evidence rated as high 5
• Serum sickness-like reactions to rituximab are more common in patients with autoimmune diseases (78-85% of cases) and may respond well to systemic glucocorticoids, with a strength of evidence rated as moderate 1
• Severe delayed reactions like DRESS, SJS, or TEN are not amenable to desensitization and require drug avoidance, with a strength of evidence rated as high 1

Follow-up Monitoring

• Monitor for resolution of skin manifestations after methylprednisolone administration, assess for any signs of infection, and document reaction details to guide management of future rituximab administrations, with a strength of evidence rated as high 1, 5

Rituximab-Associated Adverse Effects in Fibrotic Hypersensitivity Pneumonitis

Common and Serious Side Effects

• Gastrointestinal side effects, including nausea, vomiting, diarrhea, and abdominal pain, are frequently reported during rituximab treatment, according to Praxis Medical Insights 6
• Cytokine release syndrome can occur when rituximab interacts with CD20 on lymphocytes, leading to fever, rigors, chills, and other constitutional symptoms, as reported by the Journal of Allergy and Clinical Immunology 7 and Praxis Medical Insights 6
• Tumor lysis syndrome can develop within 12-24 hours of the first infusion, causing kidney failure, abnormal heart rhythm, and electrolyte disturbances, with manifestations including increased serum creatinine, potassium, phosphate, lactate dehydrogenase, and uric acid levels, according to the Journal of Allergy and Clinical Immunology 7
• Infusion reactions are classified by grade, with management depending on reaction severity, including same-day rechallenge at reduced infusion rate for grade 1, slowed infusion or desensitization for grade 2, and allergy specialist consultation and desensitization protocols for grade 3-4, as recommended by the Journal of Allergy and Clinical Immunology 7, 8, and 9

Preventive Measures and Screening

• Premedication with acetaminophen and antihistamines before each infusion is recommended to reduce infusion-related reactions, according to Praxis Medical Insights 6
• Screening for hepatitis B infection before initiating rituximab is essential to prevent viral reactivation, as emphasized by the Journal of Allergy and Clinical Immunology 7
• Baseline immunoglobulin levels, hepatitis B and C antibody levels, and screening for latent tuberculosis should be performed prior to administering rituximab, as recommended by the Mayo Clinic Proceedings 10

Dosing and Administration

• The standard dosing for rituximab in autoimmune conditions is typically two 1000-mg doses given two weeks apart, according to the Mayo Clinic Proceedings 10

Rituximab Administration Protocol

Premedication and Infusion Reactions

• Premedication with antihistamines (such as diphenhydramine 25-50 mg) and acetaminophen (650 mg) should be administered 30 minutes before infusion, as recommended by the Journal of Allergy and Clinical Immunology 11
• For moderate reactions, a stepwise increase protocol starting at 10 mL/h for 15 minutes, then 20 mL/h for 15 minutes, gradually increasing to 125 mL/h if tolerated, is suggested by the Journal of Allergy and Clinical Immunology 11
• For severe reactions, adding prednisone (50 mg PO) or methylprednisolone (40 mg IV) before attempting rechallenge, and following the same gradual titration protocol as for moderate reactions, is recommended by the Journal of Allergy and Clinical Immunology 11

Infusion-Related Reactions

• Infusion-related reactions are most common with the first infusion (occurring in up to 20% of patients) and decrease in frequency with subsequent infusions, according to the British Journal of Dermatology 12

Management of Rituximab Infusion Reactions

Immediate Management and Reaction Grading

• The American Academy of Allergy, Asthma, and Immunology recommends management of rituximab infusion reactions be stratified by reaction grade, with Grade 1 reactions managed with same-day rechallenge at reduced infusion rate after symptom resolution, Grade 2 reactions requiring shared decision-making, and Grade 3-4 reactions mandating allergy specialist consultation and formal desensitization protocols 13
• The severity classification guides all management decisions, with Grade 1A reactions involving purely cutaneous symptoms, Grade 1B involving skin manifestations plus back pain or hypertension, Grade 2 involving urticaria, nausea, vomiting, and throat tightness, Grade 3 involving symptomatic bronchospasm, dyspnea, hypoxia, and wheezing, and Grade 4 involving anaphylaxis or hypotension 13

Grade-Specific Rechallenge Strategies

• For Grade 1 reactions, same-day rechallenge is safe and recommended, with a wait for complete symptom resolution, resumption of infusion at 50% of the original rate, and no additional premedication typically required 13
• For Grade 2 reactions, management requires clinical judgment, with options including slowed infusion rate, enhanced premedication, graded challenge protocol, and formal desensitization in specialized centers 13
• For Grade 3-4 reactions, mandatory allergy specialist consultation and formal desensitization protocols are required, with desensitization using 2-bag, 8-step protocols and completion within 1 day 13

Special Considerations

• Patients with circulating malignant cells ≥25,000/mm³ require special precautions, including increased risk of cytokine release syndrome, and may require prophylactic plasmapheresis if IgM ≥4000 mg/dL 14, 15
• Severe non-immediate reactions, including DRESS, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Acute Generalized Exanthematous Pustulosis, are not amenable to desensitization and require permanent drug discontinuation 13

Monitoring Requirements

• Continuous monitoring for at least 2 hours during infusion, with vital signs every 15-30 minutes, immediate assessment if any symptoms develop, and emergency equipment readily available 13
• Monitoring should continue 1-2 hours after infusion completion, as most reactions occur within 30-120 minutes of infusion start 13

Common Pitfalls to Avoid

• Never assume subsequent infusions are safe after a Grade 3 reaction, as all such patients had recurrent reactions upon rechallenge 13
• Do not overlook hepatitis B screening, as reactivation can cause fulminant hepatic failure and death 13
• Avoid resuming infusion at full rate, and always reduce to 50% rate after reaction resolution 13
• Do not attempt desensitization outside specialized centers, as it requires experienced staff and intensive monitoring 13